echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The differentiation in the pharmaceutical and biological industry is intensified, so don't miss the opportunity to get on the six main lines

    The differentiation in the pharmaceutical and biological industry is intensified, so don't miss the opportunity to get on the six main lines

    • Last Update: 2020-01-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical network pharmaceutical stock market] looking forward to 2020, policies such as volume purchasing and consistency evaluation may become normalized At the same time, with the continuous deepening of medical reform policies, the pattern of pharmaceutical and biological industry will continue to change, the industry structure will continue to optimize, and the internal differentiation of the industry will further intensify In this context, the industry suggests focusing on several main lines In recent years, with the normalization of new policies such as consistency evaluation, volume purchase and auxiliary drug restriction, the growth differentiation within the pharmaceutical sector has been intensified Some insiders believe that, in 2020, with the promotion of national centralized procurement and further acceleration of the pace of medical reform, R & D driven and clinical application value will become the main standard to measure the value and growth of enterprises, and intensified internal differentiation will become the new normal for the development of pharmaceutical and biological industries The data shows that in the first three quarters of 2019, among the 314 pharmaceutical and biological enterprises of a share, there are 40 with a year-on-year growth rate of more than 50% in net profit attributable to shareholders of the parent company, 51 with a growth rate of 30% - 50%, 109 with a growth rate of 0-30%; 106 with a performance decline or loss However, from the perspective of each industry segment, the top growth rate of net profit are biopharmaceuticals, medical services, medical devices, APIs and chemicals, pharmaceutical businesses and proprietary Chinese medicines On the whole, the performance of most pharmaceutical companies has achieved positive growth, but the performance differentiation is relatively serious It is recommended to pay attention to the six main lines of innovative drugs In 2020, the number of varieties to be collected will be affected by the expansion of the whole country, and the growth will be under great pressure However, a large number of medical insurance negotiation varieties and new product listing are expected to offset some of the negative effects and promote the transformation of the industry from generic drugs to innovative drugs, so innovative drugs have a huge growth space It is suggested to pay attention to Hengrui pharmaceutical, a leading company Main line of characteristic API At the beginning of January 2020, the Ministry of industry and information technology and other four departments recently jointly issued the guidance on promoting the green development of API industry, which will usher in the opportunity of characteristic API market It is suggested to pay attention to the small and fine characteristic API company, minoua Main line of blood products With the improvement of medical treatment level, the enhancement of residents' health awareness and payment ability, the increase of clinical symptoms and the acceleration of aging process, the demand side of blood products is booming It is suggested to pay attention to Tiantan biology and Hualan biology, the industry leaders Vaccine mainline With the release of vaccine management method and technical guidelines for vaccine clinical comparability research, the R & D threshold of vaccine may be further improved, and the industry will gradually improve It is suggested that Kangtai biology, Zhifei biology and Changchun hi tech, the industry leaders, should take the lead Cro mainline According to the data of iResearch, in 2018, the market size of the domestic cro industry is about 67.8 billion yuan, and it is expected to expand to 97.5 billion yuan by 2020 China's cro market has a huge space With the gradual increase of industry concentration, leading enterprises are expected to usher in a golden development period It is suggested to pay attention to the leading drugs, such as mingkant, tiger medicine and kailaiying In addition, the industry believes that the country is promoting volume procurement, promoting the outflow of prescriptions from multiple perspectives such as variety structure and prescription source Therefore, the top enterprises in the retail pharmacy industry will continue to enjoy the policy dividend in the future It is suggested to pay attention to the leading people, dashanlin and Yifeng pharmacies of chain drugstores In addition to these six main lines, companies with valuation and growth, including Lizhu group, Shandong Pharmaceutical glass, Dongcheng pharmaceutical, etc., also deserve attention.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.